INmune Bio Inc. (INMB)

Market Cap	34.75M -26.1%
Revenue (ttm)	n/a +257.1%
Net Income	-16.67M
EPS	-0.62
Shares Out	30.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	677,056
Open	1.180
Previous Close	1.175
Day's Range	1.060 - 1.260
52-Week Range	1.060 - 2.600
Beta	0.94
Analysts	Buy
Price Target	7.00 (+519.47%)
Earnings Date	Nov 5, 2026

About INMB

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2019
• Employees: 21
• Stock Exchange: Nasdaq
• Ticker Symbol: INMB
• Website: https://www.inmunebio.com

Financial Performance

In 2025, INmune Bio's revenue was $50,000, an increase of 257.14% compared to the previous year's $14,000. Losses were -$45.93 million, 9.15% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for INMB stock is "Buy." The 12-month stock price target is $7.0, which is an increase of 519.47% from the latest price.

Price Target

$7.0

(519.47% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 7, 2026

Data Sources Report a data error